SWOG clinical trial number
S9631

A Cross-Sectional Study to Estimate the Incidence of Endometrial Pathology in Women Receiving Tamoxifen on SWOG-9313 (INT-0137, CALGB 9394, NCCTG 93-30-51)

Closed
Phase
Accrual
1%
Abbreviated Title
Incidence of Endometrial Pathology in Women Receiving Tamoxifen
Activated
02/01/1998
Closed
03/01/2000
Participants
NCORP, Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, NCCTG, CALGB

Research committees

Breast Cancer

Eligibility Criteria Expand/Collapse

Patients on SWOG-9313 (INT-0137, CALGB 9394, NCCTG 93-30-51))

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase